The role of interleukin-12 (IL-12) in Th1 cell differentiation is well established. The heterodimer p70, composed of a p40 and a p35 chain, is the biologically active form. IL-12 production by human monocytes is enhanced by interferon-γ (IFN-γ) and inhibited by IL-10 and prostaglandin E2 (PGE2 ). Peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected individuals reportedly have impaired IL-12 p40 and p70 production on stimulation with Staphylococcus aureus Cowan I (SAC) in vitro. Both PGE2 and IL-10 previously were proposed to be instrumental in this defect in IL-12 production. Here, we studied IL-12 p40 and p70 production in relation to IL-10 and PGE2 production in whole blood cultures from HIV-infected individuals. On stimulation with lipopolysaccharide, IL-12 production was normal. However, on stimulation with SAC, IL-12 p40 and p70 production was decreased in HIV-infected individuals and correlated significantly with decreased peripheral blood CD4+ T-cell number and T-cell reactivity to CD3 monoclonal antibody in vitro. However, IL-10 and PGE2 production in cultures from HIV-infected individuals was normal and did not relate to IL-12 production. In conclusion, IL-12 production by cells from HIV-infected individuals is impaired under certain conditions in vitro and this decrease is independent of IL-10 or PGE2 production.

HUMAN IMMUNODEFICIENCY virus-1 (HIV-1) infection is characterized by functional defects of T cells in vitro, which are observed in early infection, even before the loss of peripheral blood CD4+ T cells. The fact that both CD4+ and CD8+ T cells of HIV-infected individuals are disturbed in their function1,2 in a stage of infection in which the number of infected T cells is low3 asks for a systemic explanation for the observed T-cell dysfunction. One powerful mechanism of immune dysregulation is a disturbance of cytokine networks induced by persistent HIV infection. When T-cell dysfunction in HIV-infected individuals is studied in more detail, it is clear that functional properties ascribed to Th1 cells are specifically disturbed. Proliferation of T cells in response to ligation of the T-cell receptor CD3 complex is impaired1,4-6 and interleukin-2 (IL-2) production is decreased.2,7 Furthermore, antigen-induced interferon-γ (IFN-γ) production8 and delayed-type hypersensitivity (DTH) reactions are decreased.9,10 Shearer et al11 have been the first to propose a shift to Th2 cytokine patterns to explain T-cell dysfunction and failure of immune control of HIV-1 replication. Indeed, on generation of T-cell clones an increase in Th0 clones can be observed in HIV-infected individuals.12 13 The general conclusion from these data might be that there is a decrease in Th1-type cytokine production causing a disturbance of the balance between Th1 and Th2 responses, leading to a Th0-like cytokine profile.

In addition to the Th cytokines themselves, cytokines that are responsible for polarization of Th-type responses, are of interest. Disturbance of the production of these cytokines might provide a systemic explanation for the changes in the cytokine balance on HIV infection. IL-12 plays a critical role in Th1 cell differentiation.14 It is a cytokine consisting of two chains, p35 and p40, that is only biologically active in the heterodimeric p70 form.15 The single p40 chain is secreted in excess over p70, but no biological function is known for this protein. Chehimi et al16 have reported that peripheral blood mononuclear cells (PBMCs) from HIV-infected individuals are impaired in IL-12 p40 and p70 production on stimulation with Staphylococcus aureus antigen. This would be suggestive for an underlying failure to produce the required amount of IL-12 to mount proper Th1 responses. So far, there have been few other reports supporting the data of Chehimi et al, and we here set out to study these findings in more detail.

In recent years, several possible regulators of IL-12 production have been identified. IL-12 production is initiated by pathogens in antigen-presenting cells and can then be further enhanced by IFN-γ, the production of which is induced by IL-12 itself in T cells and natural killer cells.17 Inhibition of IL-12 production can be achieved by IL-10,18 which is also induced by IL-12 itself in T cells, possibly as a negative feedback mechanism.19 Although Chehimi et al16 suggested that increased IL-10 production does not play a role in the decreased IL-12 production in HIV infection, others have argued that increased IL-10 production does play a key role in the Th1 deficiency in HIV infection.20 Next to IL-10, prostaglandin E2 (PGE2 ) was shown to be a potent inhibitor of IL-12 production in an IL-10–independent fashion and was proposed to play a role in decreased IL-12 production in HIV infection.21 

Here, we studied IL-12 p40 and p70 production in vitro from HIV-infected individuals. To avoid preactivation of monocytes, a whole blood culture system was used, which allows for rapid analysis of many samples.21 Furthermore, we quantified IL-10 and PGE2 in the same samples, to study whether they might be responsible for altered IL-12 production in HIV infection.

Study population.PB from HIV-infected individuals enrolled in the Amsterdam cohort study on HIV infection in homosexual men was used. From all participants, absolute lymphocyte counts and T-cell subset analyses were routinely determined by fluorescence-activated cell sorting analysis using standard procedures. As controls, PBMC from non-HIV–infected healthy cohort participants was used. These controls belonged to the same risk-group as the HIV-infected cohort participants.

Cell cultures.Blood obtained by venipuncture in the morning in sodium heparin-containing sterile blood collecting tubes (VT-100 H tubes; Venoject, Terumo Europe N.V., Leuven, Belgium) was 1:10 diluted in Iscove's modified Dulbecco's medium containing 0.1% fetal calf serum, 15 IU/mL heparin (Leo Pharmaceutical Products, Weesp, The Netherlands), and antibiotics. All media were ultrafiltrated by means of a hollow fiber dialyzer (Hemoflow F5; Fresenius A.G., Bad Homburg, Germany). The same day, diluted whole blood was cultured in triplicate cultures in 96-well culture plates containing 200 μL/well.

Cultures were either stimulated or not stimulated with Neisseria meningitides-derived lipopolysaccharide (LPS; kind gift from Dr J. Poolman, RIVM, The Netherlands) or S aureus Cowan strain (SAC; Pansorbin; Calbiochem-Behring Corp, La Jolla, CA) at various concentrations as indicated in the figures. Supernatants were harvested after 20 hours of culture and stored at −70°C until further analysis.

Cytokine assays.IL-12 p40 production was determined in an enzyme-linked immunosorbent assay (ELISA) as previously described.21 IL-12 p70 production was determined in an ELISA as described,22 identical to the IL-12 p40 ELISA using p70-specific monoclonal antibody (MoAb) 20C2 as a coating antibody (kindly provided by Dr M. Gately, Hoffmann La Roche, Nutley, NJ). The IL-6 ELISA was performed as described21 using a modification of the procedure described by Helle et al.23 IL-10 production was determined in an ELISA following the protocol described by Abrams24 using MoAb 9D7 and 12G8, which were purchased from Pharmigen (San Diego, CA). For assessment of PGE2 production, a commercial ELISA was used following the instructions of the manufacturer (Boehringer Mannheim, Germany).

Statistical analysis.Data were statistically analyzed using SPSS software. For comparison of groups, the Mann Whitney U-test was used; correlations were tested for significance using the Spearman's rank correlation test. Differences and correlations were considered significant at P < .05.

Analysis of cytokine production in whole blood cultures.A whole blood culture system was used to assess monokine production by blood cells essentially following procedures as previously described.21 The cells were not processed by density gradient centrifugation; thus, the chances that the peripheral blood monocytes were preactivated are as small as possible. The IL-12 production in PBMCs is approximately 10-fold less than in that of whole blood cultures.21 Moreover, the latter is not as laborious and requires only very little patient material. In all experiments cells were cultured for 20 hours. IL-12 production was optimal after 16 hours and stayed at the same level for up to 48 hours (data not shown). We determined the optimal concentration of SAC and LPS to induce IL-12 and IL-10 production in these cultures. Whole blood from four HIV-infected individuals and three controls was stimulated with increasing concentrations of SAC and LPS, and IL-12 p40 and p70 as well as IL-10 production in the supernatant was measured. SAC was a poor inducer of IL-10 as compared with LPS (Fig 1C), whereas IL-12 p40 and p70 were induced well (Figs 1A and B). The optimal concentration for IL-12 p70 production was 0.032%, whereas p40 production had a less restricted range for optimal induction, ranging from 0.002% to 0.016%. LPS was a potent inducer of IL-12 p40 (Fig 1D) and IL-10 (Fig 1F ), whereas it was a poor inducer of IL-12 p70 (Fig 1E). For IL-12 p40 production, the highest production was achieved with LPS concentrations ranging from 10 to 150 pg/mL, whereas IL-10 increased with higher concentrations of LPS.

Fig. 1.

SAC and LPS induced IL-12 p40 and p70 production in whole blood cultures. Whole blood (diluted 1:10) from four HIV-infected individuals (closed symbols) and three noninfected controls (open symbols) was cultured in the presence of various concentrations of SAC (A through C) or LPS (D through F ). After 20 hours of culture, supernatants were harvested, and IL-12 p40 (A and D), IL-12 p70 (B and E), and IL-10 (C and F ) concentrations were measured in ELISA. The results of one representative experiment of three are shown.

Fig. 1.

SAC and LPS induced IL-12 p40 and p70 production in whole blood cultures. Whole blood (diluted 1:10) from four HIV-infected individuals (closed symbols) and three noninfected controls (open symbols) was cultured in the presence of various concentrations of SAC (A through C) or LPS (D through F ). After 20 hours of culture, supernatants were harvested, and IL-12 p40 (A and D), IL-12 p70 (B and E), and IL-10 (C and F ) concentrations were measured in ELISA. The results of one representative experiment of three are shown.

Close modal

It is important to note that the time period between the moment of blood collection and initiation of the culture negatively influenced IL-12 production. IL-12 p40 production typically decreased with about 50% over the first 8-hour time period, whereas p70 production started to decrease almost immediately and continued to decrease over time until, at 8 hours, only 10% to 30% of the production after 1 hour was left (data not shown).

SAC-induced IL-12 production is decreased in HIV-infected individuals.For experiments with groups of HIV-infected individuals and controls, the blood was processed as soon as possible, and the average time between collection of blood and the start of the experiments was the same in HIV-infected individuals and control groups. To be able to study both suboptimal and optimal stimulation conditions for all cytokines, we used 0.002%, 0.008%, and 0.032% SAC and 50, 1,250, and 5,000 pg/mL LPS for stimulation of the cultures. IL-12 p40 production was induced to about the same extent by SAC and LPS in controls. In contrast, after stimulation with SAC we observed a significantly lower IL-12 p40 production in the HIV-infected individuals (Figs 2A and B). Under the same conditions, IL-12 p70 production, which in the control group was strongly induced at high concentrations of SAC, was significantly decreased in HIV-infected individuals (Fig 2C). LPS is a very poor inducer of IL-12 p70, and there was no difference between the two groups (Fig 2D). IL-6 was induced more potently by LPS than by SAC, but, under both conditions, IL-6 production was similar in the HIV-infected individuals and in the control group.

Fig. 2.

IL-12 p40 and p70 production in whole blood cultures of HIV-infected individuals in response to LPS is normal but, in response to SAC, is decreased. Whole blood (diluted 1:10) from HIV-infected individuals (closed symbols; n = 58) and noninfected controls (open symbols, n = 36) was cultured in the presence of various concentrations SAC (A,C, and E) or LPS (B,D, and F ). After 20 hours of culture, supernatants were harvested, and IL-12 p40 (A and B), IL-12 p70 (C and D), and IL-6 (E and F ) concentrations were measured in ELISA. Mean cytokine production is shown; bars indicate the standard error of the mean. IL-12 p40 and IL-12 p70 production in HIV-infected individuals differed significantly from that in noninfected controls at 0.002% SAC (P = .03), 0.008% SAC (P < .005), and 0.032% SAC (P < .005) and at 0.002% SAC (P < .005), 0.008% SAC (P < .005), and 0.032% SAC (P < .005), respectively, as determined in the Mann-Whitney U-test.

Fig. 2.

IL-12 p40 and p70 production in whole blood cultures of HIV-infected individuals in response to LPS is normal but, in response to SAC, is decreased. Whole blood (diluted 1:10) from HIV-infected individuals (closed symbols; n = 58) and noninfected controls (open symbols, n = 36) was cultured in the presence of various concentrations SAC (A,C, and E) or LPS (B,D, and F ). After 20 hours of culture, supernatants were harvested, and IL-12 p40 (A and B), IL-12 p70 (C and D), and IL-6 (E and F ) concentrations were measured in ELISA. Mean cytokine production is shown; bars indicate the standard error of the mean. IL-12 p40 and IL-12 p70 production in HIV-infected individuals differed significantly from that in noninfected controls at 0.002% SAC (P = .03), 0.008% SAC (P < .005), and 0.032% SAC (P < .005) and at 0.002% SAC (P < .005), 0.008% SAC (P < .005), and 0.032% SAC (P < .005), respectively, as determined in the Mann-Whitney U-test.

Close modal

SAC-induced IL-12 production decreases with progression to disease.Thus, IL-12 p40 and p70 production on SAC stimulation at certain concentrations was decreased in HIV-infected individuals. We investigated whether this was related to the stage of infection of the patients as reflected by the number of peripheral blood CD4+ T cells, a predictive marker for progression to disease. IL-12 p40 and p70 production on SAC stimulation was positively correlated with CD4+ T-cell number, implying that IL-12 production decreases with progression to disease (Fig 3A). In addition, in the Amsterdam Cohort, T-cell reactivity in vitro to CD3 MoAb is measured routinely, which is a progression marker independent of CD4+ T-cell counts.25 There was a significant correlation of SAC-induced IL-12 production with T-cell reactivity (Fig 3B). In Fig 3, this is shown for stimulation with 0.008% SAC, but IL-12 p40 and p70 production also correlated significantly with CD4+ T-cell number and reactivity to CD3 MoAb on stimulation with 0.032% SAC (data not shown). One should note that, although correlations of CD4+ T-cell counts, T-cell reactivity, and IL-12 production are significant, the correlation coefficients are not very high.

Fig. 3.

IL-12 production in response to SAC decreases with progression to disease. IL-12 p40 (open symbols, dotted lines) and IL-12 p70 (closed symbols, solid lines) production in whole blood cultures from 55 HIV-infected individuals on 20 hours culture in the presence of 0.008% SAC was plotted against CD4+ T-cell number as PB (A) or T-cell reactivity to CD3 MoAb in vitro25 (B). Correlations were analyzed with the Spearman's rank correlation test. Correlations of CD4+ T-cell counts with IL-12 p40 and with IL-12 p70 were R = .50, P < .005, and R = .44, P < .005, respectively. Correlations of T-cell reactivity with IL-12 p40 and with IL-12 p70 were R = .50, P < .005, and R = .45, P < .005, respectively.

Fig. 3.

IL-12 production in response to SAC decreases with progression to disease. IL-12 p40 (open symbols, dotted lines) and IL-12 p70 (closed symbols, solid lines) production in whole blood cultures from 55 HIV-infected individuals on 20 hours culture in the presence of 0.008% SAC was plotted against CD4+ T-cell number as PB (A) or T-cell reactivity to CD3 MoAb in vitro25 (B). Correlations were analyzed with the Spearman's rank correlation test. Correlations of CD4+ T-cell counts with IL-12 p40 and with IL-12 p70 were R = .50, P < .005, and R = .44, P < .005, respectively. Correlations of T-cell reactivity with IL-12 p40 and with IL-12 p70 were R = .50, P < .005, and R = .45, P < .005, respectively.

Close modal

Decreased SAC-induced IL-12 production is not associated with increased IL-10 or increased PGE2 production in HIV-infected individuals.Because IL-10 and PGE2 are potential inhibitors of IL-12, we investigated the levels in the same supernatants in which we measured IL-12. IL-10 was induced by SAC to the same extent in HIV-infected individuals and controls (Fig 4A). High-level production of IL-10 was induced by LPS, which was not increased in HIV-infected individuals. At the two lowest concentrations of LPS, IL-10 release was even significantly decreased in HIV-infected individuals (Fig 4B). PGE2 induced by SAC and LPS was produced to the same extent in HIV-infected individuals and the control group (Figs 4C and D).

Fig. 4.

IL-10 and PGE2 production in whole blood cultures of HIV-infected individuals in response to LPS and SAC is normal. Whole blood (diluted 1:10) from HIV-infected individuals (closed symbols) and noninfected controls (open symbols) was cultured in the presence of various concentrations SAC (A and C) or LPS (B and D). After 20 hours of culture, supernatants were harvested, and IL-10 (A and B; HIV−, n = 35; HIV+, n = 55) and PGE2 (C and D; HIV−, n = 20; HIV+, n = 22) concentrations were measured in ELISA. Mean cytokine production is shown; bars indicate the standard error of the mean. IL-10 production in the HIV-infected group was significantly decreased from that in noninfected controls at 50 pg/mL LPS (P = .049) and 1,250 pg/mL (P = .01) as determined in the Mann-Whitney U-test.

Fig. 4.

IL-10 and PGE2 production in whole blood cultures of HIV-infected individuals in response to LPS and SAC is normal. Whole blood (diluted 1:10) from HIV-infected individuals (closed symbols) and noninfected controls (open symbols) was cultured in the presence of various concentrations SAC (A and C) or LPS (B and D). After 20 hours of culture, supernatants were harvested, and IL-10 (A and B; HIV−, n = 35; HIV+, n = 55) and PGE2 (C and D; HIV−, n = 20; HIV+, n = 22) concentrations were measured in ELISA. Mean cytokine production is shown; bars indicate the standard error of the mean. IL-10 production in the HIV-infected group was significantly decreased from that in noninfected controls at 50 pg/mL LPS (P = .049) and 1,250 pg/mL (P = .01) as determined in the Mann-Whitney U-test.

Close modal

Thus, whereas SAC-induced IL-12 production is decreased in HIV-infected individuals, PGE2 and IL-10 production are normal. This suggests that there is no inverse relation between PGE2 or IL-10 production with IL-12 p40 or p70 production in HIV-infected individuals. We calculated the correlation coefficients of IL-12 p40 or p70 production with PGE2 or IL-10 production, and, indeed, no significant correlation was found.

We showed that, on stimulation with LPS in vitro, IL-12 production in whole blood cultures from HIV-infected individuals equals that of controls. However, on stimulation with SAC, IL-12 p40 and p70 production is decreased in HIV-infected individuals, and this decrease in IL-12 production significantly correlates with decreased peripheral blood CD4+ T-cell number and T-cell reactivity to CD3 MoAb in vitro. However, IL-12 production was already lower in the patients with CD4+ T-cell counts greater than 500/μL, which suggests, as has been observed before,16 that the IL-12 deficiency may be a relatively early phenomenon in HIV infection.

In addition, we found that IL-10 and PGE2 production in cultures from HIV-infected individuals is normal and does not relate to IL-12 production. The decreased IL-12 production in HIV-infected individuals was not caused by decreased numbers of monocytes present in the cultures or by a general refractoriness in monocytes, because IL-6 could be induced to normal levels in cells from HIV-infected individuals by SAC.

The decreased IL-12 p40 and p70 on SAC stimulation in whole blood cultures is in agreement with the data obtained in PBMCs with SAC stimulation by Chehimi et al.16 A similar finding was obtained after stimulation with T gondii antigen for IL-12 p40.26 However, alveolar macrophages from asymptomatically infected individuals produce increased amounts of IL-12 p70 when stimulated with SAC, and decreased IL-12 secretion was only found in patients with acquired immunodeficiency syndrome (AIDS).27 Denis et al,27 as well as Chougnet et al20 who studied IL-12 and IL-10 mRNA, proposed an important role for IL-10 in the downregulation of IL-12 production in HIV-infected individuals. However, we found that IL-10 production does not relate to IL-12 production in HIV-infected individuals, which is in agreement with Chehimi et al,16 who reported that the decrease in IL-12 production in PBMCs from HIV-infected individuals, in their hands, is not accompanied by high IL-10 production. Although IL-10 is capable of downregulating IL-12 production and anti–IL-10 will upregulate IL-12 production,18 20 this occurs to the same extent in cultures from HIV-infected individuals and controls16; therefore, there is no proof for a causal role of IL-10 in decreased IL-12 production in HIV infection in vitro or in vivo.

The potent downregulation in vitro of IL-12 production by PGE221 was also proposed as a mechanism by which IL-12 production by monocytes from HIV-infected individuals is suppressed,21,28 although, so far, no experimental data on this have been published. Our data argue against a direct role for PGE2 in downregulating IL-12 production. This might be because of the fact that optimal PGE2 levels are reached around the moment of optimal IL-12 production and are too late to inhibit IL-12 production.29 However, because IL-12 and PGE2 have opposing roles in the development of Th1 cells,29 preserved PGE2 production in the presence of decreased IL-12 production may be instrumental in shifting the cytokine balance away from Th1 cell development in HIV-infected individuals. Furthermore, increased PGE2 concentrations have been reported in serum from AIDS patients,30 which might imply a role for PGE2 in downregulating IL-12 production in vivo.

Although SAC and LPS are capable of inducing IL-12 p40 production to the same extent, SAC is more potent in inducing IL-12 p70 production in this system. This is probably related to the finding that, in whole blood cultures stimulated with LPS, IL-10 is induced up to seven times as efficiently as in cultures stimulated with SAC. Endogenous IL-10 might be responsible for lower IL-12 p70 production in these cultures. Indeed, the addition of neutralizing IL-10 MoAb to LPS-stimulated cultures enhances IL-12 p70 production, whereas no effect of neutralizing IL-10 on p70 production was observed in SAC-stimulated cultures (van der Pouw Kraan et al, unpublished data).

Although SAC and LPS are equally efficient in inducing IL-12 p40 production, p40 production was only decreased in whole blood cultures from HIV-infected individuals stimulated with SAC. This suggests that SAC and LPS induce IL-12 production via a different mechanism, and only the pathway used by SAC is affected in HIV-infected individuals. LPS exclusively stimulates monocytes via the CD14 molecule. The mechanism by which SAC stimulates monocytes is not exactly known; however, because it is a crude bacterium preparation, it may well be possible that it also contains antigens that are able to stimulate T cells.31 If so, IL-12 production in SAC-stimulated cultures might be more dependent on T-cell–derived factors such as IFN-γ17 or CD40L expression32,33 than that in LPS-stimulated cultures would be. T cells of HIV-infected individuals are impaired in IFN-γ production8 and CD40L expression (Brugnoni et al34 and Wolthers et al, manuscript submitted). Thus, the possibility that decreased IL-12 production in HIV infection, in fact, is secondary, reflecting a defect in CD4+ T cells, cannot be ruled out. However, this defect in Th1 function of T cells could still reflect an IL-12 defect in vivo. HIV infection in vitro of monocyte-derived macrophages results in decreased IL-12 production (Chehimi et al16 and our own unpublished observations). Monocytes in PB are not infected with HIV,3 but the macrophages in the tissues, important for antigen presentation, are and might be incapable of inducing proper Th1 responses because of impaired IL-12 production.35 

Because of its potent immunoregulatory function in vitro, IL-12 has been proposed as an immunotherapeutic agent in HIV infection. Indeed, IL-12 is capable of enhancing proliferation of T cells from HIV-1–infected individuals in response to influenza, HIV-1 peptides,36,37,Mycobacterium avium,38,39 and polyclonal T-cell stimulators.39 Furthermore, IFN-γ production in response to several T-cell stimulators in vitro is enhanced on IL-12 addition,36,39,40 and cloning T cells from HIV-1–infected individuals in the presence of IL-12 results in an increased outgrowth of IFN-γ–producing cells.41 It should be noted that, in most publications, it was reported that proliferation and IFN-γ release by T cells from non-HIV–infected controls is also enhanced by IL-12.38,39 The enhanced outgrowth of IFN-γ–producing T cells in the presence of IL-12 is also observed when T cells from noninfected controls are used.41-44 This suggests that lack of IL-12 is not the only factor responsible for decreased Th1 function in HIV infection but, at least in vitro, enhances Th1-mediated responses, which is also observable in normal individuals. However, it can be anticipated that IL-12 treatment will support Th1 cellular immune responses in HIV-infected individuals to a certain extent.

We are indebted to all participants in the Amsterdam Cohort Studies for their continuous cooperation. We thank N. Albrecht-van Lent, M. Knapen, and R. Keet at the Municipal Health Service for their help in collecting the patient samples and Dr R. van Lier for critical review of the manuscript.

Supported by a grant from the Netherlands Organization for Scientific Research (900-506-208). Performed as part of the Amsterdam Cohort Studies on AIDS, a collaboration between the Municipal Health Service, the Academic Medical Centre, and the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.

Address reprint requests to Frank Miedema, Department of Clinical Viro-Immunology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands.

1
Miedema
F
Petit
AJC
Terpstra
FG
Schattenkerk
JKME
De Wolf
F
Al BJM
Roos MThL
Lange
JMA
Danner
SA
Goudsmit
J
Schellekens
PThA
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs.
J Clin Invest
82
1988
1908
2
Gruters
RA
Terpstra
FG
De Jong
R
Van Noesel
CJM
Van Lier
RAW
Miedema
F
Selective loss of T-cell functions in different stages of HIV infection.
Eur J Immunol
20
1990
1039
3
Schnittman
SM
Psallidopoulos
MC
Lane
HC
Thompson
L
Baseler
M
Massari
F
Fox
CH
Salzman
NP
Fauci
AS
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4.
Science
245
1989
305
4
Shearer
GM
Bernstein
DC
Tung
KSK
Via
CS
Redfield
R
Salahuddin
SZ
Gallo
RC
A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS).
J Immunol
137
1986
2514
5
Giorgi
JV
Fahey
JL
Smith
DC
Hultin
LE
Cheng
HL
Mitsuyasu
RT
Detels
R
Early effects of HIV on CD4 lymphocytes in vivo.
J Immunol
138
1987
3725
6
Ballet
JJ
Couderc
LJ
Rabian-Herzog
C
Duval-Roy
C
Janier
M
Danon
F
Clauvel
JP
Seligmann
M
Impaired T-lymphocyte-dependent immune responses to microbial antigens in patients with HIV-1-associated persistent generalized lymphadenopathy.
AIDS
2
1988
291
7
Clerici
M
Via
CS
Lucey
DR
Roilides
E
Pizzo
PA
Shearer
GM
Functional dichotomy of CD4+ T helper lymphocytes in asymptomatic human immunodeficiency virus infection.
Eur J Immunol
21
1991
665
8
Murray
HW
Scavuzzo
DA
Kelly
CD
Rubin
BY
Roberts
RB
T4+ cell production of interferon gamma and the clinical spectrum of patients at risk for and with acquired immunodeficiency syndrome.
Arch Intern Med
148
1988
1613
9
Blatt
SP
Hendrix
CW
Butzin
CA
Freeman
TM
Ward
WW
Hensley
RE
Melcher
GP
Donovan
DJ
Boswell
RN
Delayed type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients.
Ann Intern Med
119
1993
177
10
Markowitz
N
Hansen
NI
Wilcosky
TC
Hopewell
PC
Glassroth
J
Kvale
PA
Mangura
BT
Osmond
D
Wallace
JM
Rosen
MJ
Reichman
LB
Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons.
Ann Intern Med
119
1993
185
11
Clerici
M
Hakim
FT
Venzon
DJ
Blatt
S
Hendrix
CW
Wynn
TA
Shearer
GM
Changes in interleukin-2 and interleukin-4 production in asymptomatic human immunodeficiency virus-seropositive individuals.
J Clin Invest
91
1993
759
12
Maggi
E
Mazzetti
M
Ravina
A
Annunziato
F
De Carli
M
Pesce
AM
Del Prete
G
Romagnani
S
Ability of HIV to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells.
Science
265
1994
244
13
Meyaard
L
Otto
SA
Keet
IPM
Van Lier
RAW
Miedema
F
Changes in cytokine secretion patterns of CD4+ T-cell clones in HIV-1 infection.
Blood
84
1994
4262
14
Hsieh
C-S
Macatonia
SE
Tripp
CS
Wolf
ST
O'Gara
A
Murphy
KM
Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages.
Science
260
1993
547
15
Trinchieri
G
Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes.
Blood
84
1994
4008
16
Chehimi
J
Starr
SE
Frank
I
D'Andrea
A
Ma
X
MacGregor
RR
Sennelier
J
Trinchieri
G
Impaired interleukin 12 production in human immunodeficiency virus infected patients.
J Exp Med
179
1994
1361
17
Kubin
M
Chow
JM
Trinchieri
G
Differential regulation of interleukin-12 (IL-12), tumor necrosis factor α, and IL-1β production in human myeloid leukemia cell lines and peripheral blood mononuclear cells.
Blood
83
1994
1847
18
D'Andrea
A
Aste-Amezaga
M
Valiante
NM
Ma
X
Kubin
M
Trinchieri
G
Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells.
J Exp Med
178
1993
1041
19
Meyaard
L
Hovenkamp
E
Otto
SA
Miedema
F
IL-12–induced IL-10 production by human T cells as a negative feedback for IL-12–induced immune responses.
J Immunol
156
1996
2776
20
Chougnet
C
Clerici
M
Shearer
GM
Role of IL-12 in HIV disease/AIDS.
Res Immunol
146
1995
615
21
Van der Pouw
Kraan TCTM
Boeije
LCM
Smeenk
RJT
Wijdenes
J
Aarden
LA
Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.
J Exp Med
181
1995
775
22
Jansen
PM
Van der Pouw
Kraan TCTM
De Jong
IW
van Mierlo
G
Wijdenes
J
Chang
AA
Aarden
LA
Taylor
FB
Hack
CE
The release of interleukin-12 (IL-12) in experimental Escherichia coli septic shock in baboons: Relation to plasma levels of IL-10 and interferon γ.
Blood
87
1996
5144
23
Helle
M
Boeije
L
De Groot
ER
De Vos
A
Aarden
LA
Sensitive ELISA for interleukin 6. Detection of IL-6 in biological fluids: Synovial fluids and sera.
J Immunol Methods
138
1991
47
24
Abrams
JS
Roncarolo
MG
Yssel
H
Andersson
U
Gleich
GJ
Silver
J
Strategies of anti-cytokine monoclonal antibody development: Immunoassay of IL-10 and IL-5 in clinical samples.
Immunol Rev
127
1992
5
25
Schellekens
PThA
Roos
MThL
De Wolf
F
Lange
JMA
Miedema
F
Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for AIDS in HIV-1 infected men.
J Clin Immunol
10
1990
121
26
Gazzinelli
RT
Bala
S
Stevens
R
Baseler
M
Wahl
L
Kovacs
J
Sher
A
HIV infection suppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but fails to inhibit the synthesis of other parasite-induced monokines.
J Immunol
155
1995
1565
27
Denis
M
Ghadirian
E
Dysregulation of interleukin 8, interleukin 10, and interleukin 12 release by alveolar macrophages from HIV type 1-infected subjects.
AIDS Res Hum Retroviruses
10
1994
1619
28
Chehimi J, Paganin C, Frank I, Chouaib S, Starr SE, Trinchieri G: Interleukin-12 in the pathogenesis and therapy of HIV disease. Res Immunol 605, 1996
29
Hilkens
CMU
Snijders
A
Vermeulen
H
Van der Meide
PH
Wierenga
EA
Kapsenberg
ML
Accessory cell-derived IL-12 and prostaglandin E2 determine the IFN-gamma level of activated human CD4+ T cells.
J Immunol
156
1996
1722
30
Delemarre
FGA
Stevenhagen
A
Kroon
FP
Van Eer
MY
Meenhorst
PL
Van Furth
R
Reduced toxoplasmastatic activity of monocytes and monocyte-derived macrophages from AIDS patients is mediated via prostaglandin E2.
AIDS
9
1995
441
31
Ishizaka
A
Sakiyama
Y
Takahashi
Y
Matsumoto
S
The activation of T cells with Staphylococcus aureus Cowan 1 (SAC).
Immunol Lett
10
1985
13
32
Shu
U
Kiniwa
M
Wu
CY
Maliszewski
C
Vezzio
N
Hakimi
J
Gately
M
Delespesse
G
Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction.
Eur J Immunol
25
1995
1125
33
Stüber
E
Strober
W
Neurath
M
Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion.
J Exp Med
183
1996
693
34
Brugnoni
D
Prati
E
Airò
P
Castelli
F
Cattaneo
R
The ability of CD4+ T cells from HIV+ individuals to express CD40 ligand after in vitro stimulation is not impaired.
Clin Immunol Immunopathol
74
1995
112
35
Meyaard
L
Schuitemaker
H
Miedema
F
T-cell dysfunction in HIV infection: Anergy due to defective antigen presenting cell function?
Immunol Today
14
1993
161
36
Clerici
M
Lucey
DR
Berzofsky
JA
Pinto
LA
Wynn
TA
Blatt
SP
Dolan
MJ
Hendrix
CW
Wolf
SF
Shearer
GM
Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro.
Science
262
1993
1721
37
Blauvelt
A
Chougnet
C
Shearer
GM
Katz
SI
Modulation of T cell responses to recall antigens presented by Langerhans cells in HIV-discordant identical twins by anti-interleukin (IL)-10 antibodies and IL-12.
J Clin Invest
97
1996
1550
38
Newman
GW
Guarnaccia
JR
Vance
III EA
Wu
J-Y
Remold
HG
Kazanjian
Jr PH
Interleukin-12 enhances antigen-specific proliferation of peripheral blood mononuclear cells from HIV-positive and negative donors in response to Mycobacterium avium.
AIDS
8
1994
1413
39
Seder
RA
Grabstein
KH
Berzofsky
JA
McDyer
JF
Cytokine interactions in human immunodeficiency virus-infected individuals: Roles of interleukin (IL)-2, IL-12 and IL-15.
J Exp Med
182
1995
1067
40
Zhang
M
Gong
J
Iyer
DV
Jones
BE
Modlin
RL
Barnes
PF
T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection.
J Clin Invest
94
1994
2435
41
Paganin
C
Frank
I
Trinchieri
G
Priming for high interferon-gamma production induced by interleukin-12 in both CD4+ and CD8+ T cell clones from HIV-infected patients.
J Clin Invest
96
1995
1677
42
Manetti
R
Parronchi
P
Giudizi
MG
Piccinni
M-P
Maggi
E
Trinchieri
G
Romagnani
S
Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.
J Exp Med
177
1993
1199
43
Manetti
R
Gerosa
F
Giudizi
M-G
Biagiotti
R
Parronchi
P
Piccinni
M-P
Sampognaro
S
Maggi
E
Romagnani
S
Trinchieri
G
Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones.
J Exp Med
179
1994
1273
44
Yssel
H
Fasler
S
De Vries
JE
De Waal
Malefyt R
IL-12 transiently induces IFN-gamma transcription and protein synthesis in human CD4+ allergen-specific Th2 T cell clones.
Int Immunol
6
1994
1091
Sign in via your Institution